SANTA CLARA, Calif., Oct. 19, 2018 /PRNewswire/ -- SI-BONE, Inc. (Nasdaq: SIBN) ("SI-BONE"), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced the closing of its initial public offering of 8,280,000 shares of common stock, at a price to the public of $15.00 per share, including the full exercise by the underwriters of their option to purchase an additional 1,080,000 shares of common stock. All of the shares of common stock were offered by SI-BONE. The shares began trading on The Nasdaq Global Market under the ticker symbol "SIBN" on October 17, 2018.
Morgan Stanley and BofA Merrill Lynch acted as joint book-running managers. Canaccord Genuity LLC and JMP Securities LLC acted as co-managers.
The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or email at [email protected].
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
SOURCE SI-BONE, Inc.